Related Experiment Videos

Antiplatelet versus anticoagulant therapies in advanced age: an unfinished task

Antonio García-Honrubia, Vanessa Roldán, Vicente Climent

    International Journal of Cardiology
    |December 14, 2005
    PubMed

    Insights

    The best antithrombotic therapy for atrial fibrillation (AF) remains controversial. While anticoagulants are recommended, aspirin’s role and warfarin selection in elderly patients require further investigation.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Medicine

    Background:

    • The optimal antithrombotic strategy for patients with atrial fibrillation (AF) is a subject of ongoing debate.
    • Retrospective studies, such as that by Blich and Gross, highlight the persistent controversy surrounding the best treatment approach.
    • Randomized controlled trials support anticoagulant therapy for stroke prevention in AF, but comparisons with aspirin suggest varying effectiveness.

    Discussion:

    • While aspirin demonstrates efficacy in preventing stroke in AF patients, direct and indirect comparisons indicate it may be less effective than oral anticoagulation.
    • The generalizability of findings from clinical trials to real-world patient populations is questioned.
    • The precise role of antiplatelet therapy in AF management requires further clarification.

    Key Insights:

    • Anticoagulant therapy is a cornerstone for stroke prevention in atrial fibrillation.
    • Aspirin offers some benefit but appears less effective than anticoagulation for stroke prevention in AF.
    • Patient selection for antithrombotic therapy, particularly the choice between aspirin and warfarin in the elderly, remains a critical unresolved issue.

    Outlook:

    • Further research is needed to establish definitive guidelines for antithrombotic therapy in diverse AF patient groups.
    • Investigating the efficacy and safety of different antithrombotic agents in specific patient subgroups, including the elderly, is crucial.
    • Clarifying the role of antiplatelet agents in conjunction with or as an alternative to anticoagulation in AF management is warranted.

    Related Concept Videos

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Drug Dosing: Geriatric Patients01:15

    Drug Dosing: Geriatric Patients

    Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
    Pharmacodynamics in Geriatric Patients: Effects of Age01:27

    Pharmacodynamics in Geriatric Patients: Effects of Age

    Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...